BioSpace News Archive

HighField Biopharmaceuticals2 other diseases, said naturally occurred diabetic monkeys experienced weight loss and HbA1c level reduction during an assessment period of two months following a single injection with HFG1.

Airway Therapeutics, Inc. announced it received the Whitsett Award for highest scoring abstracts from the Neonatal and Developing Lung Executive Committee at the American Thoracic Society 2024 International Conference.

Fractyl Health, Inc. announced that it will accelerate its REMAIN-1 clinical study, which is evaluating Revita’s efficacy in maintaining weight loss following the discontinuation of GLP-1 therapy.

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical program updates for IDE397, a potential first-in-class Phase 2 MAT2A inhibitor targeting MTAP-deletion solid tumors.

NanoViricides, Inc., a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum antiviral NV-387 could be an important weapon against bird flu H5N1 viruses.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety of trilaciclib administered prior to chemotherapy in patients with metastatic TNBC.

BioNTech SE and Duality Biologics Co., Ltd. announced that the U.S. Food and Drug Administration granted Fast Track designation for BNT324/DB-1311 for the treatment of patients with advanced/unresectable, or metastatic castration-resistant prostate cancer who have progressed on or after standard systemic regimens.

Asensus Surgical, Inc. announced that St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan has entered into an agreement to lease and utilize a Senhance® Surgical System in the Urology and Gastroenterology/General Surgery department.

ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc. announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.